We propose here that down-regulation of mutant p53 activity, down-regulation of the Mcl-1 protein, and inhibition of aberrant Akt phosphorylation can provide promising therapeutic strategies for combination treatment with chemotherapy in a subset of patients with FLT3-ITD-positive AML. This evidence concerns the gene AKT1 and acute myeloid leukemia.